A leading provider in the healthcare industry, projects a remarkable compound annual growth rate (CAGR) and a substantial market value for the Short Bowel Syndrome (SBS) market. With an estimated CAGR of [CAGR] 15.4% and a projected market value of US$ 728.3 million in 2030 the company anticipates significant growth opportunities and advancements in the treatment and management of SBS. This positive outlook reflects the commitment of to addressing the unmet medical needs of patients suffering from this challenging condition.
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/137
Key Development:
• In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. Food and Drug Administration had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912).
• In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases, for the prevention of acute graft-versus-host disease (aGVHDc